SARC025 arms 1 and 2: A phase 1 study of the poly(ADP‐ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma-Reference-Cited by-同舟云学术

SARC025 arms 1 and 2: A phase 1 study of the poly(ADP‐ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma

Published:2020-12-08 Issue:8 Volume:127 Page:1301-1310
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Chugh Rashmi¹,Ballman Karla V.²,Helman Lee J.³,Patel Shreyaskumar⁴,Whelan Jeremy S.⁵,Widemann Brigitte⁶,Lu Yao²,Hawkins Douglas S.⁷^ORCID,Mascarenhas Leo³^ORCID,Glod John W.⁶,Ji Jiuping⁸,Zhang Yiping⁸,Reinke Denise⁹^ORCID,Strauss Sandra J.⁵¹⁰^ORCID

Affiliation:

1. Division of Hematology/Oncology University of Michigan Ann Arbor Michigan

2. Population Health SciencesWeill Cornell Medicine New York New York

3. Cancer and Blood Disease Institute Children's Hospital of Los Angeles, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California Los Angeles California

4. Department of Sarcoma The University of Texas MD Anderson Cancer Center Houston Texas

5. Department of Oncology University College London Hospitals NHS Trust London United Kingdom

6. Pediatric Oncology Branch National Cancer Institute Center for Cancer Research Bethesda Maryland

7. Seattle Children's Hospital Seattle Washington

8. National Clinical Target Validation Laboratory National Cancer Institute Center for Cancer Research Bethesda Maryland

9. Sarcoma Alliance for Research Through Collaboration Ann Arbor Michigan

10. University College London Cancer Institute London United Kingdom

Funder

National Cancer Institute

GlaxoSmithKline

National Institutes of Health

National Institute for Health Research